[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650412":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":45,"collaborators":11,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":11,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":11,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":69,"whyStopped":11,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Pyrotech Therapeutics, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants receiving PTT-621 Dose A","EXPERIMENTAL",null,[13],"Drug: PTT-621 Tablets",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","PTT-621 Tablets","PTT-621 will be administered orally",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Ran Wei","CONTACT","+86 10 81938094","ran.wei@pyrotech.com",[27],{"facility":28,"status":11,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Renji Hospital-Shanghai Jiao Tong University School of Medicine","Shanghai","Shanghai Municipality","200127","China","CN",{"type":35,"coordinates":36},"Point",[37,38],121.45806,31.22222,{"lat":38,"lon":37},[41],{"name":42,"role":23,"phone":43,"phoneExt":11,"email":44},"Qi Lu","+86 21 68383575","rjirbzc@vip.163.com",{"type":46,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100650412","phase-2-a-study-to-evaluate-the-efficacy-safety-tolerability-and-pharmacokinetics-of-ptt-621-in-patients-with-moderately-to-severely-active-ulcerative-colitis-100650412",false,"NCT07747155","A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of PTT-621 in Patients With Moderately to Severely Active Ulcerative Colitis","A Phase IIa, Multicenter, Single-Arm Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Characteristics of PTT-621 in Patients With Moderately to Severely Active Ulcerative","Inclusion Criteria:\n\n* 1\\. Male or female participants aged 18-70 years inclusive at screening. 2. Diagnosed with ulcerative colitis (UC) at least 60 days prior to the first dose of IP.\n\n  3\\. Participants have active UC at screening, defined as a modified Mayo score of 5-9.\n\n  4\\. Endoscopic evidence of UC extending ≥15 cm from the anal verge during the screening period.\n\n  5\\. Participants have had inadequate\u002Floss of response or intolerance to at least one of the following: 5-aminosalicylic acid, glucocorticoids, immunosuppressants, biologics, and\u002For small-molecule targeted therapies.\n\n  6\\. Participants currently receiving the following UC therapies are eligible if they meet stability requirements: Oral glucocorticoids: with stable dosing for ≥2 weeks prior to screening endoscopy；Oral 5-ASA: Stable dose for at least 2 weeks prior to the endoscopic assessment during the screening period.\n\n  7\\. Female participants of childbearing potential must have a negative serum\u002Furine pregnancy test at screening.\n\n  8\\. Willing to use at least one highly effective contraceptive method during sexual intercourse throughout the study and until 1 month after the last dose of IP.\n\n  9\\. Willing to refrain from sperm\u002Fova donation throughout the study and until 1 month after the last dose of IP.\n\n  10\\. Able and willing to provide written informed consent and comply with all protocol-specified procedures and visit schedules.\n\nExclusion Criteria:\n\n* 1\\. A current diagnosis of Crohn's disease (CD), indeterminate colitis, infectious colitis, or any other colitis\u002Fenteritis that could interfere with efficacy evaluation； 2. Has UC complications (e.g., fulminant colitis, toxic megacolon, prior total or partial colectomy, or other conditions requiring surgery)； 3. Prior or current gastrointestinal dysplasia； 4. History of gastrointestinal malignancy, or any current evidence of gastrointestinal cancer.","ALL","18 Years","70 Years",{"count":58,"type":59},40,"ESTIMATED","INTERVENTIONAL",[62],"PHASE2","This Phase IIa, multicenter, single-arm trial evaluates the efficacy, safety, tolerability, and pharmacokinetics of PTT-621 tablets in adults (18-70 years) with moderate-to-severe active ulcerative colitis (UC) who have inadequate response\u002Fintolerance to standard therapies. Participants receive PTT-621 for 12 weeks. The primary endpoint is the proportion of participants achieving endoscopic improvement at Week 12. Secondary endpoints include safety, clinical remission, clinical response, symptom response, pharmacokinetics, and inflammatory biomarkers. The study is sponsored by Pyrotech Therapeutics, with ethical approval from Renji Hospital's IRB.",[65],"Ulcerative Colitis (UC)",[67,68],"Ulcerative Colitis","IBD","NOT_YET_RECRUITING","2026-08-04",{"date":72,"type":73},"2026-08-07","ACTUAL",{"date":75,"type":59},"2026-08",{"date":77,"type":59},"2028-06",{"name":5,"class":6},1]